Articles: function.
-
Physiology/PFTs/Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To compare the effect of heliox-driven (Helium 80%: Oxygen 20%) to air-driven (Nitrogen 79%; Oxygen 21%) BD therapy on PFTs in patients with different levels of severity of airway obstructions. ⋯ The following authors have nothing to disclose: Mohamad El Khatib, Ghassan Jamaleddine, Nadim Kanj, Juliette Jibrail, Marwan Alawieh, Salah Zeineddine, Imad BouAkl, Ahmad Husari, Hassan Chami, Pierre BouKhalilNo Product/Research Disclosure Information.
-
Bronchology Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Post-extubation stridor is a life-threatening condition. A variety of their causes has been established and includes obstructed secretion, vocal cord edema, vocal cord dysfunction, and tracheomalacia. In this report, we report herein a rare incidence of post-extubation stridor caused by obstructive fibrinous tracheal pseudomembrane (OFTP). ⋯ In conclusion, this report highlights the potential fatal complication of considering OFTP in patient presenting with dyspnea and inspiratory stridor after extubation, and the physician should alert and perform bronchoscopy for the precise diagnosis to allow early detection.Reference #1: Deslee G, Brichet A, Lebuffe G, Copin MC, Ramon P, Marquette CH (2000) Obstructive fibrinous tracheal pseudomembrane. A potentially fatal complication of tracheal intubation. Am J Respir Crit Care Med 162:1169-1171DISCLOSURE: The following authors have nothing to disclose: Narongwit NakwanNo Product/Research Disclosure Information.
-
Miscellaneous Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Hyperventilation refers to rapid or deep breathing and is commonly associated with panic and anxiety. Other common causes include somatisation, severe pain, infection, ketoacidosis, asthma, chronic obstructive pulmonary disease, pulmonary embolism and heart failure. ⋯ The following authors have nothing to disclose: Rui Ya Soh, Anne HsuNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The prevalence of PAH in patients with IPF is not well known. There has been no prospective study to date. The purpose of our study was to know the prevalence of PAH in patients with IPF at any stage of severity ⋯ 60 patients (18 women, age at diagnosis 64 years) were included and 56 completed the study protocol. Patient characteristics: FVC 64%, DLCO 41%, 6MWT 357 meters, systolic pulmonary arterial pressure 46 mmHg. 17 patients showed a systolic pulmonary artery pressure greater than 40 mmHg and in 14 of them PAH was confirmed by right heart catheterization with a mean pulmonary arterial pressure of 28.6 mmHg. When comparing various clinical and functional parameters between patients with and without PAH significant differences were seen in FVC, FEV1, DLCO, 6MWT and Functional Class. In a multivariate analysis DLCO was associated with the presence of PAHCONCLUSIONS: PAH is not infrequent in patients with IPF (around 26%).Patients with more severe disease are more likely to develop PAH. A marked decrease in DLCO is independently associated with the presence of PAHCLINICAL IMPLICATIONS: PAH is a devastating disease with prognostic and therapeutic implications in patients with IPF. To know the prevalence and associated factors in very important for a better management of this patients because we now have effective treatments in PAHDISCLOSURE: The following authors have nothing to disclose: Adolfo Villar, Julio Ancochea, Antonio XaubetNo Product/Research Disclosure Information.
-
Pulmonary Function TestingSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: Exhaled nitric oxide (FeNO) and Methacholine challenge (MCH) are both utilized in the detection and management of numerous pulmonary diseases. MCH is a measure of direct airway hyperresponsiveness. FeNO measures bronchial epithelial damage from eosinophilic bronchitis whether asthma or non-asthma related. FeNO has an attractive performance profile, as it is a cheaper and less invasive test. We hypothesize that FeNO can decrease the need for MCH testing. ⋯ The following authors have nothing to disclose: Andrew Nickels, Kenneth Parker, Paul Scanlon, Kaiser LimNo Product/Research Disclosure Information.